By the end of 2023, the COVID-19 pandemic had killed an officially recorded 7 million people worldwide — a figure that excess mortality researchers estimate understates true death tolls by a factor of two to three. Against that backdrop, global vaccination campaigns administered more than 13 billion doses across 184 countries, preventing an estimated 19.8 million deaths in the first year of rollout alone, according to research published in The Lancet. The scale of that achievement — the fastest vaccine deployment in recorded history — was not uniform. Some countries achieved coverage rates above 90 percent of their adult populations within twelve months. Others remained below 20 percent two years into the campaign. The gap between those outcomes was not primarily about vaccine availability, though supply constraints were real and severe in the early months. It was about institutional design, community trust, logistical infrastructure, and the political will to treat immunisation as a systemic programme rather than a procurement exercise.
Bangladesh sits in an instructive position in this analysis. The country vaccinated over 140 million people across its adult population — a programme of considerable logistical complexity for a nation of 170 million with health infrastructure that has historically been stretched thin. It did so faster than many comparable economies and achieved coverage rates that public health analysts have described as genuinely creditable. Yet the programme also exposed structural vulnerabilities — in rural reach, in cold chain reliability, in the data systems tracking who had and had not been vaccinated — that Bangladesh's health planners now have both the obligation and the opportunity to address before the next pandemic-scale health emergency arrives.
What the High Performers Did Differently: Chile, Portugal, and the UAE
Chile was the first middle-income country to achieve over 50 percent vaccination coverage and ultimately vaccinated more than 90 percent of its eligible population. The country's success rested on three specific design choices that public health researchers have since studied as a model. First, Chile leveraged its existing national influenza vaccination infrastructure — a programme that runs annually and has built institutional memory across its primary care network — rather than constructing a parallel COVID-19 delivery system from scratch. Second, Chile signed bilateral procurement agreements directly with manufacturers at a time when most countries were waiting for multilateral mechanisms to deliver doses, securing supply earlier in the global shortage period. Third, it used a centralised digital registry that tracked vaccination status in real time and automatically flagged gaps in coverage at the neighbourhood level, enabling targeted outreach rather than passive wait-for-patients approaches.
Portugal achieved vaccination coverage above 87 percent of its total population — not just adults — by late 2021 and was for a period the most vaccinated country in Europe. The Portuguese success has a specific institutional explanation: the country assigned its entire vaccine rollout to the military, under Admiral Henrique Gouveia e Melo, who ran the programme with the scheduling discipline of a logistics operation rather than a healthcare delivery exercise. Fixed appointments replaced walk-in availability, reducing waste and no-shows. Mobile units were deployed to reach elderly and rural populations who could not easily access fixed sites. The approach was not replicable in every political context — it depended on institutional trust in the military and a relatively compact geography — but the underlying lesson about operational discipline and accountability was widely noted.
The United Arab Emirates achieved one of the highest vaccination rates globally, exceeding 99 percent coverage of its eligible population by 2022. The UAE's advantage was partly structural — a small, urbanised population with high per capita income, a powerful centralised government, and a health system with no meaningful rural-urban disparity — but the programme also benefited from early adoption of a diverse vaccine portfolio including both mRNA and inactivated virus platforms, reducing dependence on any single supply chain. The government used its digital identity infrastructure to track vaccination status, tie vaccination to access to public spaces and events, and generate community uptake pressure that supplemented traditional communication campaigns.
Bangladesh's Vaccination Programme: What Worked and What Didn't
Bangladesh's COVID-19 vaccination programme launched in February 2021 with the Oxford-AstraZeneca vaccine supplied through the Serum Institute of India under a bilateral agreement. The early phase was built around the government's Surokkha registration platform — an app and web portal that required digital pre-registration before vaccination, a design choice with significant equity implications in a country where digital literacy and smartphone access vary sharply by age, gender, and geography. By mid-2021, Bangladesh had administered approximately 8 million doses, but supply disruption from India — which restricted exports of the Serum Institute vaccine during its devastating Delta wave — created a gap that threatened to stall the programme entirely for several months.
The disruption forced a strategic pivot that ultimately strengthened the programme. Bangladesh diversified its vaccine portfolio, acquiring Sinopharm and Moderna vaccines alongside continued AstraZeneca supply through COVAX, and accelerated mass vaccination campaigns that moved beyond the pre-registration model to reach populations who had not self-enrolled. By January 2022, Bangladesh had administered 129 million doses, and by the programme's primary phase completion, coverage of the adult population exceeded 70 percent with at least one dose and approximately 60 percent with two doses — figures that placed Bangladesh ahead of several countries with significantly higher GDP per capita.
The structural weaknesses were also real. Cold chain capacity outside Dhaka and major divisional cities remained a constraint throughout the programme, with some rural areas relying on ice-lined refrigerators rather than purpose-built vaccine storage equipment. The pre-registration requirement systematically underserved older rural populations, women in conservative communities, and people without smartphones or reliable internet connectivity — groups that paradoxically represented some of the highest clinical risk categories for severe COVID-19. Health researchers documented significant disparities in two-dose coverage between urban and rural populations, and between men and women, that persisted through the programme's primary phase.
The programme also faced misinformation challenges specific to the Bangladesh context. False claims circulating on Facebook — the dominant information platform for most Bangladeshi adults — linked the AstraZeneca vaccine to blood clotting deaths, exaggerated the frequency of side effects, and in some cases claimed that vaccines contained substances prohibited by Islamic law. Community health workers reported that vaccine hesitancy in rural areas was frequently linked to content seen on social media rather than to traditional forms of medical scepticism. The government's communication response was sometimes slow to counter specific viral false claims, relying on general reassurance messaging rather than targeted factual correction.
Expert Assessment: What Bangladesh Needs Before the Next Emergency
Bangladesh's health sector planners and international health organisations have identified several priority areas for pandemic preparedness investment that the COVID-19 experience made visible. The most consistently cited is the need for a universal, interoperable health identity system — a digital record that follows patients across healthcare encounters, tracks vaccination status, and can be used to identify coverage gaps and at-risk populations without requiring active self-registration by those populations. Several countries that performed well in COVID-19 vaccination, including South Korea and Portugal, already had robust digital health record infrastructure that was adapted for the pandemic rather than built from scratch.
Cold chain infrastructure expansion across Bangladesh's rural upazila and union parishad health facilities is a second consistently identified priority. Bangladesh's Expanded Programme on Immunisation (EPI) — one of the most successful immunisation programmes in the developing world, which drove child vaccination rates for diseases like measles, polio, and diphtheria above 95 percent — already maintains a cold chain network that reaches most of the country. The gap is in the storage capacity and reliability of that infrastructure for novel vaccines with more demanding temperature requirements than traditional EPI vaccines. mRNA vaccines, which represented the highest-efficacy options in the COVID-19 portfolio and are likely to be central to future pandemic responses, require ultra-cold storage at temperatures of -20 to -70 degrees Celsius — conditions that Bangladesh's current cold chain network is not equipped to maintain at scale outside major cities.
Community health worker capacity is a third priority. Bangladesh's network of community health workers — approximately 30,000 Community Health Care Providers (CHCPs) operating at the community clinic level across rural Bangladesh — proved critically important in reaching populations that the Surokkha platform missed. The COVID-19 experience demonstrated both the value of this network and its limitations: CHCPs are primarily trained in maternal and child health and basic primary care, and many lacked the specific training to deliver vaccine counselling, manage hesitancy, and administer injections under the conditions required by a mass vaccination emergency. Investing in training and equipping this workforce for immunisation emergencies is an investment in national preparedness capacity that also strengthens routine healthcare delivery.
The Broader Lesson: Vaccine Equity as Global Security
The COVID-19 vaccination experience produced a lesson that public health advocates had argued for decades but that the pandemic made viscerally clear: vaccine equity is not charity but epidemiology. Countries with high vaccination rates remained vulnerable to variants emerging in poorly vaccinated populations elsewhere. The Delta and Omicron variants, both of which emerged in conditions of low vaccination coverage in high-transmission environments, spread globally within weeks and reset the pandemic trajectory in countries that had believed their own vaccination programmes had brought the crisis under control. The failure to vaccinate the world fast enough was not only a moral failure — it was a strategic one, measurable in additional deaths, economic disruption, and the renewed need for restrictions in countries that had already vaccinated their populations.
For Bangladesh, this global dynamic has a specific implication: the country sits at the intersection of several epidemiological risk factors — high population density, significant informal sector employment that makes social distancing impractical, regular exposure to climate-related displacement events that concentrate populations, and integration with labour migration systems that create constant human movement across borders. Its readiness to respond to the next pandemic-scale infectious disease event matters not only for Bangladeshi lives but for the regional and global epidemiological landscape of which Bangladesh is unavoidably a part. The investments in digital health infrastructure, cold chain capacity, community health worker training, and vaccine procurement systems that COVID-19 made visible are not optional enhancements to a functioning system. They are the architecture of a system that can actually protect its population when the next emergency arrives. The countries that learned those lessons earliest from COVID-19 are already building that architecture. Bangladesh has both the institutional experience from its own rollout — which was, in its fundamentals, a genuine success — and the documented understanding of what it still needs to build.
WinTK covers Bangladesh's public health, policy, and development landscape. For more reporting and analysis, visit our news section.
